Final Thoughts on Recent Data Updates in MDS
Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.
Key Trials in the Treatment of Higher-Risk MDS
Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.
IRAK1 and IRAK4 Inhibitors for the Treatment of Lower-Risk MDS
Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.
Oral HMAs in Lower-Risk MDS Treatment
Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.
Imetelstat for Lower-Risk MDS: Data From the IMerge Trial
Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.
Luspatercept for Lower-Risk MDS: Data From the COMMANDS Trial
Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.
ESA Outcomes by SF3B1 Mutation Status in Lower-Risk MDS
Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.
Treatment Approaches for Lower-Risk MDS With RAS Mutations
The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.
Patient Profile: A 79-Year-Old Man With Lower-Risk MDS and a KRAS Mutation
Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.
Treatment Approaches for Lower-Risk MDS With Symptomatic Anemia
Panelists review the presented patient profile and shares how they would have approached treatment.
Patient Profile: A 75-Year-Old Man With Lower-Risk MDS and Symptomatic Anemia
Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.
Second-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.
Monitoring Treatment With ESAs for Lower-Risk MDS With Symptomatic Anemia
Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.
Unmet Needs and Future Perspectives in Treatment of MDS
Expert oncologists discuss unmet needs and share final thoughts on the future of treatment of patients with lower-risk MDS.
Clinical Management of Patients with Lower-risk MDS
Ralph Boccia, MD, FACP, highlights emerging therapies and the importance of next-generation sequencing for patients with MDS.
Initiating Treatment for Lower-Risk MDS With Symptomatic Anemia
The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.
First-Line Treatment Options for Lower-Risk MDS With Symptomatic Anemia
Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.
Emerging Therapies for Treatment of MDS
Expert oncologists discuss management strategies for patients with lower-risk MDS considering upcoming treatment options.
Safety and Efficacy of Luspatercept in Frontline Setting in Patients with MDS
Oncologists review study design and discuss key safety and efficacy data of the COMMANDS trial investigating luspatercept in frontline setting in patients with lower-risk MDS.
Risk Stratification of MDS
Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.
Diagnosing Myelodysplastic Syndromes (MDS)
Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.
Clinical Use of Luspatercept on Patients with Lower-risk MDS
Ralph Boccia, MD, FACP, shares his clinical experience using luspatercept to treat patient with lower-risk MDS.
Frontline Treatment Options for Lower-Risk MDS
Expert oncologists discuss standard-of-care frontline treatments for patients with lower-risk MDS.
Importance of Early Diagnosis of MDS for Lower and Higher-risk Patients
Hetty Carraway, MD, highlights the importance of early diagnosis across all patients with MDS.
Risk Stratification of Myelodysplastic Syndromes [MDS]
Ralph Boccia, MD, FACP, and Hetty Carraway, MD, review Myelodysplastic Syndromes [MDS] risk stratification criteria used in their practices.
Future Directions in the Management of Acute Myeloid Leukemia
Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.
Emerging Treatment Strategies in Acute Myeloid Leukemia
A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.
Sequencing Therapies in Patients With Relapsed/Refractory AML
Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.
A Potential Role for IDH-1 Inhibitor Olutasidenib in Relapsed/Refractory AML?
Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.
Treatment Strategies in Patients With Relapsed/Refractory AML
Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.
Axatilimab Elicits Responses With Manageable Safety in Recurrent/Refractory cGVHD
Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma
Dr Ghia on a Biomarker Analysis of the SEQUOIA Trial in CLL/SLL
Oral DEC-C Treatment Is Feasible and Comparable With IV/SC HMA Outcomes in MDS
2 Clarke Drive Cranbury, NJ 08512